Literature DB >> 29934777

Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study.

Anika Witten1, Juliane Bolbrinker2, Andrei Barysenka1, Matthias Huber2, Frank Rühle1, Ulrike Nowak-Göttl3, Edeltraut Garbe2,4, Reinhold Kreutz2, Monika Stoll5,6.   

Abstract

Immune-mediated heparin-induced thrombocytopenia (HIT) is the clinically most important adverse drug reaction (ADR) in response to heparin therapy characterized by a prothrombotic state despite a decrease in platelet count. We conducted a genome-wide association study in 96 suspected HIT cases and 96 controls to explore the genetic predisposition for HIT within a case-control pharmacovigilance study followed by replication in additional 86 cases and 86 controls from the same study. One single nucleotide polymorphism (SNP, rs1433265, P = 6.5 × 10-5, odds ratio (OR) 2.79) from 16 identified SNPs was successfully replicated (P = 1.5 × 10-4, OR 2.77; combined data set P = 2.7 × 10-8, OR 2.77) and remained the most strongly associated SNP after imputing locus genotypes. Fine mapping revealed a significantly associated risk-conferring haplotype (P = 4.9 × 10-6, OR 2.41). In order to find rare variants contributing to the association signals, we applied a targeted resequencing approach in a subgroup of 73 HIT patients and 23 controls for the regions with the 16 most strongly HIT-associated SNPs. C-alpha testing was applied to test for the impact of rare variants and we detected two candidate genes, the discoidin domain receptor tyrosine kinase 1 (DDR1, P = 3.6 × 10-2) and the multiple C2 and transmembrane domain containing 2 (MCTP2, P = 4.5 × 10-2). For the genes interactor of little elongation complex ELL subunit 1 (ICE1) and a disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 16 (ADAMTS16) nearby rs1433265, we identified several missense variants. Although replication in an independent population is warranted, these findings provide a basis for future studies aiming to identify and characterize genetic susceptibility factors for HIT. KEY MESSAGES: We identified and validated a HIT-associated locus on chromosome 5. Targeted NGS analysis for rare variants identifies DDR1 and MCTP2 as novel candidates. In addition, missense variants for ADAMTS16 and ICE1 were identified in the locus.

Entities:  

Keywords:  ADAMTS16; ADR; GWAS; HIT; ICE1

Mesh:

Substances:

Year:  2018        PMID: 29934777     DOI: 10.1007/s00109-018-1661-6

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  62 in total

1.  A linear complexity phasing method for thousands of genomes.

Authors:  Olivier Delaneau; Jonathan Marchini; Jean-François Zagury
Journal:  Nat Methods       Date:  2011-12-04       Impact factor: 28.547

2.  Heparin-Induced Thrombocytopenia.

Authors:  Andreas Greinacher
Journal:  N Engl J Med       Date:  2015-11-05       Impact factor: 91.245

Review 3.  Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors.

Authors:  Jérôme Rollin; Claire Pouplard; Yves Gruel
Journal:  Thromb Haemost       Date:  2016-06-30       Impact factor: 5.249

Review 4.  Heparin-induced thrombocytopenia: a review.

Authors:  Bruno Girolami; Antonio Girolami
Journal:  Semin Thromb Hemost       Date:  2006-11       Impact factor: 4.180

5.  A genome-wide association study identifies a gene network of ADAMTS genes in the predisposition to pediatric stroke.

Authors:  Astrid Arning; Milan Hiersche; Anika Witten; Gerhard Kurlemann; Karin Kurnik; Daniela Manner; Monika Stoll; Ulrike Nowak-Göttl
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

6.  Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia.

Authors:  Claire Pouplard; Pascale Cornillet-Lefebvre; Redha Attaoua; Dorothée Leroux; Carinne Lecocq-Lafon; Jérôme Rollin; Florin Grigorescu; Philippe Nguyen; Yves Gruel
Journal:  Thromb Res       Date:  2012-01-10       Impact factor: 3.944

Review 7.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

Review 8.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

Review 9.  Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.

Authors:  Thomas L Ortel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 10.  Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. A systematic review and meta-analysis.

Authors:  Lova Sun; Phyllis A Gimotty; Suvasini Lakshmanan; Adam Cuker
Journal:  Thromb Haemost       Date:  2016-01-14       Impact factor: 5.249

View more
  5 in total

1.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

Review 2.  Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Authors:  Gowthami M Arepally; Anand Padmanabhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

3.  PharmGKB summary: heparin-induced thrombocytopenia pathway, adverse drug reaction.

Authors:  Elise Miller; Charles Norwood; Jason B Giles; Rachel Huddart; Jason H Karnes; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2022-04-01       Impact factor: 2.089

Review 4.  Quantitative and Qualitative Platelet Derangements in Cardiac Surgery and Extracorporeal Life Support.

Authors:  Enrico Squiccimarro; Federica Jiritano; Giuseppe Filiberto Serraino; Hugo Ten Cate; Domenico Paparella; Roberto Lorusso
Journal:  J Clin Med       Date:  2021-02-06       Impact factor: 4.241

Review 5.  Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.

Authors:  Jason B Giles; Elise C Miller; Heidi E Steiner; Jason H Karnes
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.